Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into companion diagnostics and expanded therapeutic options for cancer patients. Co.'s third generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Co. to discover new cancer sub-types molecular diagnostics cannot detect. Co.'s proprietary CELsignia diagnostic platform is commercially ready technology that uses a patient's living tumor cells to evaluate the functional status of the cell signaling pathways associated with cancer. The CELC stock yearly return is shown above.
The yearly return on the CELC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CELC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|